- Home
- CTRM vs ATOS Comparison
CTRM vs ATOS Comparison
Compare CTRM & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRM | ATOS |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 24.1M |
| IPO Year | 2017 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CTRM | ATOS |
|---|---|---|
| Price | $2.41 | $2.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 49.8K | ★ 53.4K |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $0.53 |
| 52 Week High | $2.66 | $7.56 |
Technical Indicators
Market Signals| Indicator | CTRM | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 41.80 |
| Support Level | $2.01 | $2.32 |
| Resistance Level | $2.44 | $2.60 |
| Average True Range (ATR) | 0.15 | 0.14 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 43.33 | 11.23 |
Price Performance
Historical ComparisonAbout CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments, namely (i) the dry bulk segment, (ii) the containership segment, and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.